β-Blocker Therapy in Veterans with Asthma or Chronic Obstructive Pulmonary Disease

Barnett, Mitchell J.; Milavetz, Gary; Kaboli, Peter J.

doi:10.1592/phco.2005.25.11.1550

Cited by 26 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The actions of beta-blocker were different in the lipophilicity, cardioselectivity, and vasodilatation. Drugs, such as carvedilol, metoprolol and labetalol are lipid solubility and have peripheral vasodilators effects; other drugs, such atenolol and practolol are not lipid solubility and not have peripheral vasodilator effects, moreover possess cardiac selectivity 10,28,29 .…”

Section: ■ Discussionmentioning

confidence: 99%

“…Activated polymorphonuclear neutrophils (PMN) and proinflammatory cytokines are then released into the systemic circulation, interact with the vascular endothelium of distant organs, therefore, contributing to the systemic inflammatory response 8,9 . Atenolol (an earlier-generation beta-1-selective blocker) is an antihypertensive agent with cardiac selectivity offer theoretical advantages over non-selective drugs in patients with bronchial asthma, peripheral vascular disease 10 , decreased cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension 11 . Here we tested the hypothesis that treatment with AT would 2-0 suture, opened for clamp removal and closed again until the end of reperfusion (the intestinal tract was placed between gauze pads that had been soaked with warmed 0.9% NaCl solution).…”

Section: ■ Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of atenolol pre-treatment in heart damage in a model of intestinal ischemia-reperfusion

et al. 2017

View full text Add to dashboard Cite

1 AbstractPurpose: To investigate the effects of atenolol in inflammatory mediator and oxidative stress in a myocardial injury by intestinal ischemia/reperfusion in rat model. Methods: Adult Wistar male rats were randomly (n=8), anesthetized and divided in: Sham: submitted to operation only; group SS+IR: intravenous saline infusion following superior mesenteric artery occlusion during 60 minutes (ischemia) and open for 120 minutes (reperfusion); group AT+IR: intravenous atenolol infusion (2 mg/kg) following superior mesenteric artery occlusion during 60 minutes (ischemia) and open for 120 minutes (reperfusion); and group AT+I+AT+R: intravenous atenolol infusion following superior mesenteric artery occlusion during 60 minutes (ischemia) and in the time 45 minutes other atenolol doses were administrated and the artery was open for 120 minutes (reperfusion), all animals were submitted to muscular relaxation for mechanical ventilation. In the end of experiment the animals were euthanized and the hearts tissue were morphology analyzed by histology and malondialdehyde by ELISA, and the plasma were analyzed for tumor necrosis factor-alpha by ELISA. Results:The group SS+IR demonstrated the higher malondialdehyde levels when compared with the atenolol treated-groups (p=0.001) in the heart tissue. The tumor necrosis factoralpha level in plasma decrease in the treated groups when compared with SS+IR group (p=0.001). Histology analyses demonstrate pyknosis, edema, cellular vacuolization, presence of inflammatory infiltrate and band contraction in the heart tissue of the rats. Conclusion: Atenolol significantly reduce the degree of cardiac damage after intestinal ischemia-reperfusion.

show abstract

Section: ■ Discussionmentioning

confidence: 99%

Section: ■ Introductionmentioning

confidence: 99%

Effect of atenolol pre-treatment in heart damage in a model of intestinal ischemia-reperfusion

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Salpeter et al [34] and Camsari et al [35] noted no difference in forced expiratory volume in the first second with the use of cardioselective β-blockers and no attenuation of the beneficial pulmonary effects of β2-agonists. Barnett et al [36] did not find an increase in hospitalization or outpatient visits for COPD or asthma in patients taking cardioselective β-blockers. Kotlyar et al [37] similarly demonstrated that carvedilol was also well tolerated in patients with HF and COPD.…”

Section: Pulmonary Diseasementioning

confidence: 91%

Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure

Tsai¹,

Klapholz²

2007

Curr Heart Fail Rep

View full text Add to dashboard Cite

beta-blockade has a therapeutic role across the continuum of patients with heart failure (HF), with a demonstrated mortality benefit in stage II and III HF. Concerns regarding initiation and uptitration linger as patients with resting bradycardia, pulmonary, or vascular disease are often unnecessarily excluded from receiving therapy. We will review the risk data on beta-blockade and offer therapeutic strategies to help overcome residual barriers to the initiation and uptitration of this important therapy in patients with HF.

show abstract

“…The HR for hospital admission for asthma or COPD during the observation year was not different for patients taking and not taking BB and no difference was noted with selective versus nonselective beta-blockers. Curiously enough, the hospital admission rate was lower with atenolol than metoprolol [105].…”

Section: Exacerbationsmentioning

confidence: 95%

“…In another study 8390 individuals with a diagnosis of asthma or COPD and receiving treatment with a BB or another cardiovascular agent were identified in 2000-2001 from three Veterans Administration databases in Iowa and Nebraska (USA) ( Table 3) [105]. The HR for hospital admission for asthma or COPD during the observation year was not different for patients taking and not taking BB and no difference was noted with selective versus nonselective beta-blockers.…”

Section: Exacerbationsmentioning

confidence: 99%

Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses

Álvarez-Sala

Miguel-Díez

2015

COPD Res Pract

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease is prevalent condition commonly associated with cardiovascular diseases. When both are combined the prognosis of the patient worsens. One cornerstone therapy for most cardiac diseases is beta-blockade, however concerns about its potential harmful effects on airways function often restrains their use in patients with COPD and coexistent cardiac diseases. While selective beta 1 adrenergic blockers seem to have a better safety profile, other non-selective beta-blockers can be securely utilized in stable COPD patients with no or little reactivity when they are indispensable and used with caution. Evidence provided by post hoc analysis of clinical trials and large observational studies suggests a beneficial effect of beta-blockers on mortality and exacerbations in mild to moderate COPD patients. Benefits are less obvious in severe COPD. Studies on the actual use of beta-blockers suggest that many cardiac patients with COPD (or vice versa) who can benefit from beta-blocker utilization do not receive such medication as it is recommended in the guidelines because of die-hard, not justified in most cases, concerns on safety.

show abstract

β-Blocker Therapy in Veterans with Asthma or Chronic Obstructive Pulmonary Disease

Abstract: Patients taking beta-blockers did not have more hospital admissions or clinic visits for their asthma or COPD than patients not taking these agents. When clinically indicated, beta-blockers-especially atenolol-should be considered for patients with asthma or COPD.

Cited by 26 publications

References 32 publications

Effect of atenolol pre-treatment in heart damage in a model of intestinal ischemia-reperfusion

Effect of atenolol pre-treatment in heart damage in a model of intestinal ischemia-reperfusion

Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure

Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses

Contact Info

Product

Resources

About